#China #Shanghai #KJ-C2219 #CARsgen Therapeutics #CD19/CD20 CAR-T

CARsgen Therapeutics Takes a Bold Step with New CAR-T Therapy

In a monumental leap for cancer treatment, CARsgen Therapeutics Holdings Limited has successfully administered the first dose of its innovative allogeneic CAR-T cell therapy, KJ-C2219, in an investigator-initiated trial. Targeting the CD19 and CD20 proteins, this therapy aims to combat hematologic malignancies, particularly focusing on relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

The Therapy Behind KJ-C2219

KJ-C2219 emerges from CARsgen’s advanced THANK-u Plus platform, a cutting-edge technology that enhances their proprietary THANK-uCAR® system. This platform was designed with a unique focus: to maximize therapeutic efficacy by addressing NKG2A expression levels found on NK (natural killer) cells. Preclinical studies have shown that THANK-u Plus allows for sustained cell expansion, significantly outperforming the previous iteration, the THANK-uCAR®. As a result, therapies utilizing this platform—such as the dual-targeting CD19/CD20 CAR-T cells—have demonstrated robust antitumor activity, especially in the presence of NK cells, opening up new possibilities for allogeneic therapies.

Investigation and Trials

The ongoing trial in China is pivotal for the assessment of KJ-C2219’s effectiveness against malignancies known for their stubborn resistance to treatment. Investigators are eager to unravel its potential to improve patient outcomes for those battling hematologic cancers that are often challenging to manage.

CARsgen's Commitment to Innovation

CARsgen Therapeutics operates on a global scale, with a significant presence in both the U.S. and China. The company prides itself on its dedication to developing viable CAR T-cell therapies that can tackle various forms of cancer. Their comprehensive research and development platform encompasses target discovery, innovative therapy creation, and clinical trial management, as well as large-scale production capabilities.

CARsgen's mission is to address major challenges within the CAR T-cell therapy landscape, including improving safety profiles, enhancing efficacy while treating solid tumors, and minimizing treatment costs. With a robust proprietary technology pipeline, they aspire to emerge as a global leader in the field of biopharmaceuticals, significantly contributing to the future of cancer treatment.

Looking Ahead

KJ-C2219's introduction signals a promising new chapter not only for CARsgen but for the many patients grappling with cancer's complexities. As they continue to push the boundaries of innovation, CARsgen remains dedicated to delivering groundbreaking therapies that could one day render cancer a curable disease.

For those interested in learning more about CARsgen Therapeutics and their next steps in the world of CAR-T therapies, further information is available on their official website, www.carsgen.com.

Forward-looking Statements

It is crucial to note that the company offers forward-looking statements in its communications. These statements reflect the company's beliefs and projections regarding future events that are subject to various risks and uncertainties, which could lead to significant deviations from anticipated outcomes. As highlighted in their recent reports, CARsgen encourages potential stakeholders to review the outlined risks for a comprehensive understanding of the company’s operational landscape.